KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217).

Masaki Tanaka, Hiroyuki Ono, Kohei Takizawa, Shintaro Iwamoto, Yusuke Sano, Seiichiro Abe, Tomohiro Kadota, Takuya Wada, Akiyoshi Ishiyama, Hiroyoshi Nakanishi, Shinji Nagata, Haruhiko Fukuda, Manabu Muto, Tomonori Yano, Gastrointestinal Endoscopy Study Group of the Japan Clinical Oncology Group

Dig Endosc 38(6) e70195

PMID42313516
PMCIDPMC13277963
DOI10.1111/den.70195
发表日期2026-06-18
入排依据:While this is a Phase III randomized oncology trial with drug interventions and a time-to-event endpoint (stricture-free survival), the primary endpoint is prevention of a post-procedural complication (esophageal stricture), not a direct oncology efficacy endpoint for the malignant neoplasm itself. Therefore, it does not meet the specific requirement for a primary/key secondary oncology efficacy endpoint (OS, PFS, DFS, etc.).
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 km;FIGURE 3:AI 判定为 multi panel km。
摘要

摘要

OBJECTIVES: Endoscopic local triamcinolone injection is a standard therapy for esophageal stricture (ES) prevention after extensive endoscopic submucosal dissection (ESD); however, oral prednisolone administration is a promising alternative. This trial aimed to investigate the superiority of oral prednisolone administration to local triamcinolone injection for ES prevention after extensive ESD. METHODS: This phase 3, open-label, multicenter, randomized controlled trial enrolled patients with extensive superficial esophageal squamous cell carcinoma. The primary endpoint was stricture-free survival (SFS). Secondary endpoints were the number of endoscopic balloon dilations (EBDs) for 12 weeks after ESD, dysphagia score ≤ 1 at 12 weeks after ESD, and adverse events (AEs). RESULTS: A total of 281 patients from 45 institutions were enrolled. The 12-week SFS rates were 88.5% (95% confidence interval [CI]: 81.6-92.9) and 94.8% (95% CI: 89.4-97.5) in the triamcinolone and prednisolone arms, respectively (hazard ratio 0.672, 90% CI [0.361-1.250], p = 0.14). Thirty-eight and 26 EBDs were performed for 14 and 10 patients, respectively, in the triamcinolone and prednisolone arms within 12 weeks after ESD. In the triamcinolone and prednisolone arms, 73.8% (95% CI: 65.7-80.8) and 80.7% (95% CI: 73.2-86.9) of patients, respectively, had dysphagia scores ≤ 1 at 12 weeks after ESD (p = 0.20). Grade 3/4 AEs occurred in 12 (8.7%) and 9 patients (6.7%) in the triamcinolone and prednisolone arms, respectively. CONCLUSIONS: While oral prednisolone administration and local triamcinolone injection demonstrated comparable outcomes, oral prednisolone did not demonstrate superiority for ES prevention after extensive esophageal ESD.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 2

Stricture‐free survival of both treatment arms. The Stricture‐free survival (SFS) at 12 weeks was 88.5% (95% CI: 81.6–92.9) and 94.8% (95% CI: 89.4–97.5) in the local triamcinolone arm and oral prednisolone arm, respectively (HR 0.67, 90% CI [0.361–1.250], 95% CI [0.321–1.408]; one‐sided p = 0.1442).

Stricture-free_survival

Stricture-free survival

FIGURE 2 · Panel Stricture-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Stricture-free_survival 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

FIGURE 3

(a) Stricture‐free survival (SFS) for lesions with luminal circumference of ≥ 3/4 and < 7/8. The 12‐week SFS of the cases with mucosal defect over three‐fourths to seven‐eighths of the lumen was 96.0% (95% CI: 84.9–99.0) and 96.5% (95% CI: 86.7–99.1) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 1.229, 95% CI [0.275–5.492]). (b) SFS for the lesions with luminal circumference of > 7/8 but not the whole circumference. The SFS at 12 weeks was 75.2% (95% CI: 58.8–85.8) and 92.5% (95% CI: 78.5–97.5) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 0.545, 95% CI [0.198–1.502]). (c) SFS for the lesions with a whole‐circumference mucosal defect. The SFS at 12 weeks was 50.0% (95% CI: 11.1–80.4) and 75.0% (95% CI: 12.8–96.1) in the local triamcinolone arm and the oral prednisolone arm, respectively (HR 0.360, 95% CI [0.040–3.223]).

A

Stricture-free survival

FIGURE 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Stricture-free survival

FIGURE 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Stricture-free survival

FIGURE 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1CONSORT diagram of the study. All patients will be registered before treatment and randomized. The efficacy analysis was done in the intention‐to‐treat (ITT) population, and the safety analysis was done in the per‐protocol (PP) population. AE, Adverse event.
非 KM Figure